Psychiatric comorbidity in the treatment of patients with inflammatory bowel disease

World Journal of Gastroenterology

Volumn 20, Issue 13, 2014, Pages 3552-3563

  Filipovic, Branislav R ^a,b   Filipovic, Branka F ^c  

^a Institute of Anatomy Niko Miljani   (Serbia)

^b UNIVERSITY OF BELGRADE   (Serbia)

^c Bezanijska Kosa University Medical Center   (Serbia)

Author keywords

Anxiety; Depression; Inflammatory bowel disease; Personality traits; Psychiatry; Treatment

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; AMFEBUTAMONE; AMITRIPTYLINE; ANTIBIOTIC AGENT; ANXIOLYTIC AGENT; AZATHIOPRINE; BISPHOSPHONIC ACID DERIVATIVE; BRAIN DERIVED NEUROTROPHIC FACTOR; CITALOPRAM; FLUOXETINE; FLUVOXAMINE; GLUCOCORTICOID; HYDROCORTISONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLIXIMAB; INTERLEUKIN 10; MESALAZINE; MIRTAZAPINE; MITOGEN ACTIVATED PROTEIN KINASE P38; MONOAMINE OXIDASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PAROXETINE; PHENELZINE; PREDNISOLONE; PROTON PUMP INHIBITOR; SERTRALINE; SYNAPTOTAGMIN I; TUMOR NECROSIS FACTOR ALPHA; VENLAFAXINE;

ALEXITHYMIA; ANXIETY; ARTICLE; AUTOGENIC TRAINING; BEHAVIOR THERAPY; CHRONIC STRESS; COGNITIVE THERAPY; COMORBIDITY; CROHN DISEASE; DEFECATION URGENCY; DEPRESSION; DISTRESS SYNDROME; GUILT; HUMAN; INFLAMMATORY BOWEL DISEASE; LEARNING TEST; MENTAL DISEASE; MENTAL INSTABILITY; MULTICENTER STUDY (TOPIC); NERVOUS SYSTEM INFLAMMATION; NEUROSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PREVALENCE; PSYCHODYNAMIC PSYCHOTHERAPY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHEUMATOID ARTHRITIS; SLEEP DEPRIVATION; SYSTEMATIC REVIEW (TOPIC); TORONTO ALEXITHYMIA SCALE; ULCERATIVE COLITIS; WEIGHT GAIN;

EID: 84897524011     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i13.3552     Document Type: Article

References (130)

1. Bonaz B. Inflammatory bowel diseases: a dysfunction of brain-gut interactions? Minerva Gastroenterol Dietol 2013; 59: 241-259 [PMID: 23867945]
2. Bonaz BL, Bernstein CN. Brain-gut interactions in inflammatory bowel disease. Gastroenterology 2013; 144: 36-49 [PMID: 23063970 DOI: 10.1053/j.gastro.2012.10.003]
3. Agostini A, Benuzzi F, Filippini N, Bertani A, Scarcelli A, Farinelli V, Marchetta C, Calabrese C, Rizzello F, Gionchetti P, Ercolani M, Campieri M, Nichelli P. New insights into the brain involvement in patients with Crohn's disease: a voxelbased morphometry study. Neurogastroenterol Motil 2013; 25: 147-e82 [PMID: 22998431 DOI: 10.1111/nmo.12017]
4. Vogt BA. Inflammatory bowel disease: perspectives from cingulate cortex in the first brain. Neurogastroenterol Motil 2013; 25: 93-98 [PMID: 23336589 DOI: 10.1111/nmo.12067]
5. Bernasconi N, Duchesne S, Janke A, Lerch J, Collins DL, Bernasconi A. Whole-brain voxel-based statistical analysis of gray matter and white matter in temporal lobe epilepsy. Neuroimage 2004; 23: 717-723 [PMID: 15488421 DOI: 10.1016/ j.neuroimage.2004.06.015]
6. Dolapcioglu C, Guleryuzlu Y, Uygur-Bayramicli O, Ahishali E, Dabak R. Asymptomatic brain lesions on cranial magnetic resonance imaging in inflammatory bowel disease. Gut Liver 2013; 7: 169-174 [PMID: 23560152 DOI: 10.5009/ gnl.2013.7.2.169]
7. Scheid R, Teich N. Neurologic manifestations of ulcerative colitis. Eur J Neurol 2007; 14: 483-493 [PMID: 17437605 DOI: 10.1111/j.1468-1331.2007.01718.x]
8. Agranoff D, Schon F. Are focal white matter lesions in patients with inflammatory bowel disease linked to multiple sclerosis? Lancet 1995; 346: 190-191 [PMID: 7603262]
9. Hart PE, Gould SR, MacSweeney JE, Clifton A, Schon F. Brain white-matter lesions in inflammatory bowel disease. Lancet 1998; 351: 1558 [PMID: 10326545]
10. Geissler A, Andus T, Roth M, Kullmann F, Caesar I, Held P, Gross V, Feuerbach S, Schölmerich J. Focal white-matter lesions in brain of patients with inflammatory bowel disease. Lancet 1995; 345: 897-898 [PMID: 7707814]
11. Yuan YZ, Tao RJ, Xu B, Sun J, Chen KM, Miao F, Zhang ZW, Xu JY. Functional brain imaging in irritable bowel syndrome with rectal balloon-distention by using fMRI. World J Gastroenterol 2003; 9: 1356-1360 [PMID: 12800256]
12. Vaughn C, Leff J, Sarner M. Relatives' expressed emotion and the course of inflammatory bowel disease. J Psychosom Res 1999; 47: 461-469 [PMID: 10624844]
13. Bernstein CN, Singh S, Graff LA, Walker JR, Miller N, Cheang M. A prospective population-based study of triggers of symptomatic flares in IBD. Am J Gastroenterol 2010; 105: 1994-2002 [PMID: 20372115 DOI: 10.1038/ajg.2010.140]
14. Bitton A, Dobkin PL, Edwardes MD, Sewitch MJ, Meddings JB, Rawal S, Cohen A, Vermeire S, Dufresne L, Franchimont D, Wild GE. Predicting relapse in Crohn's disease: a biopsychosocial model. Gut 2008; 57: 1386-1392 [PMID: 18390994 DOI: 10.1136/gut.2007.134817]
15. Bitton A, Sewitch MJ, Peppercorn MA, deB Edwardes MD, Shah S, Ransil B, Locke SE. Psychosocial determinants of relapse in ulcerative colitis: a longitudinal study. Am J Gastroenterol 2003; 98: 2203-2208 [PMID: 14572569 DOI: 10.1111/ j.1572-0241.2003.07717.x]
16. Duffy LC, Zielezny MA, Marshall JR, Weiser MM, Phillips JF, Byers TE, Calkins BM, Graham S, Ogra PL. Lag time between stress events and risk of recurrent episodes of inflammatory bowel disease. Epidemiology 1991; 2: 141-145 [PMID: 1932312]
17. Levenstein S, Prantera C, Varvo V, Scribano ML, Andreoli A, Luzi C, Arcà M, Berto E, Milite G, Marcheggiano A. Stress and exacerbation in ulcerative colitis: a prospective study of patients enrolled in remission. Am J Gastroenterol 2000; 95: 1213-1220 [PMID: 10811330 DOI: 10.1111/ j.1572-0241.2000.02012.x]
18. Mawdsley JE, Rampton DS. The role of psychological stress in inflammatory bowel disease. Neuroimmunomodulation 2006; 13: 327-336 [PMID: 17709955 DOI: 10.1159/000104861]
19. Gray JD, Milner TA, McEwen BS. Dynamic plasticity: the role of glucocorticoids, brain-derived neurotrophic factor and other trophic factors. Neuroscience 2013; 239: 214-227 [PMID: 22922121 DOI: 10.1016/j.neuroscience.2012.08.034]
20. Mols F, Denollet J. Type D personality among noncardiovascular patient populations: a systematic review. Gen Hosp Psychiatry 2010; 32: 66-72 [PMID: 20114130 DOI: 10.1016/ j.genhosppsych.2009.09.010]
21. Temoshok LR, Waldstein SR, Wald RL, Garzino-Demo A, Synowski SJ, Sun L, Wiley JA. Type C coping, alexithymia, and heart rate reactivity are associated independently and differentially with specific immune mechanisms linked to HIV progression. Brain Behav Immun 2008; 22: 781-792 [DOI: 10.1016/j.bbi.2008.02.003]
22. Filipović BR, Filipović BF, Kerkez M, Milinić N, Randelović T. Depression and anxiety levels in therapy-naive patients with inflammatory bowel disease and cancer of the colon. World J Gastroenterol 2007; 13: 438-443 [PMID: 17230615]
23. Acosta-Ramírez D, Pagán-Ocasio V, Torres EA, Rodríguez M, Caro O. Profile of the inflammatory bowel disease patient with depressive disorders. P R Health Sci J 2001; 20: 215-220 [PMID: 11776721]
24. Kurina LM, Goldacre MJ, Yeates D, Gill LE. Depression and anxiety in people with inflammatory bowel disease. J Epidemiol Community Health 2001; 55: 716-720 [PMID: 11553654 DOI: 10.1136/jech.55.10.716]
25. Haapamäki J, Tanskanen A, Roine RP, Blom M, Turunen U, Mäntylä J, Färkkilä MA, Arkkila PE. Medication use among inflammatory bowel disease patients: excessive consumption of antidepressants and analgesics. Scand J Gastroenterol 2013; 48: 42-50 [PMID: 23163864 DOI: 10.3109/00365521.2012.7435 84]
26. Mittermaier C, Dejaco C, Waldhoer T, Oefferlbauer-Ernst A, Miehsler W, Beier M, Tillinger W, Gangl A, Moser G. Impact of depressive mood on relapse in patients with inflammatory bowel disease: a prospective 18-month follow-up study. Psychosom Med 2004; 66: 79-84 [PMID: 14747641]
27. Porcelli P, Leoci C, Guerra V, Taylor GJ, Bagby RM. A longitudinal study of alexithymia and psychological distress in inflammatory bowel disease. J Psychosom Res 1996; 41: 569-573 [PMID: 9032720]
28. Prasko J, Jelenova D, Mihal V. Psychological aspects and psychotherapy of inflammatory bowel diseases and irritable bowel syndrome in children. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2010; 154: 307-314 [PMID: 21293541]
29. Noyes R, Hartz AJ, Doebbeling CC, Malis RW, Happel RL, Werner LA, Yagla SJ. Illness fears in the general population. Psychosom Med 2000; 62: 318-325 [PMID: 10845345]
30. Antony MM, Watling M. Overcoming Medical Phobias: How to Conquer Fear of Blood, Needles, Doctors, and Dentists. Oakland, CA: New Harbinger, 2006
31. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Text revision. Washington, DC: American Psychiatric Association, 2000
32. Armitage EL, Aldhous MC, Anderson N, Drummond HE, Riemersma RA, Ghosh S, Satsangi J. Incidence of juvenileonset Crohn's disease in Scotland: association with northern latitude and affluence. Gastroenterology 2004; 127: 1051-1057 [PMID: 15480983 DOI: 10.1053/j.gastro.2004.06.024]
33. Lehtinen P, Ashorn M, Iltanen S, Jauhola R, Jauhonen P, Kolho KL, Auvinen A. Incidence trends of pediatric inflammatory bowel disease in Finland, 1987-2003, a nationwide study. Inflamm Bowel Dis 2011; 17: 1778-1783 [PMID: 21744433 DOI: 10.1002/ibd.21550]
34. Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, Benchimol EI, Panaccione R, Ghosh S, Barkema HW, Kaplan GG. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012; 142: 46-54.e42; quiz e30 [PMID: 22001864 DOI: 10.1053/j.gastro.2011.10.001]
35. Väistö T, Aronen ET, Simola P, Ashorn M, Kolho KL. Psychosocial symptoms and competence among adolescents with inflammatory bowel disease and their peers. Inflamm Bowel Dis 2010; 16: 27-35 [PMID: 19575356]
36. Hill R, Lewindon P, Muir R, Grangé I, Connor F, Ee L, Withers G, Cleghorn G, Davies P. Quality of life in children with Crohn disease. J Pediatr Gastroenterol Nutr 2010; 51: 35-40 [PMID: 20410845 DOI: 10.1097/MPG.0b013e3181c2c0ef]
37. Kunz JH, Hommel KA, Greenley RN. Health-related quality of life of youth with inflammatory bowel disease: a comparison with published data using the PedsQL 4.0 generic core scales. Inflamm Bowel Dis 2010; 16: 939-946 [PMID: 19998462 DOI: 10.1002/ibd.21128]
38. Moody G, Eaden JA, Mayberry JF. Social implications of childhood Crohn's disease. J Pediatr Gastroenterol Nutr 1999; 28: S43-S45 [PMID: 10204525 DOI: 10.1097/00005176-199904]
39. Calsbeek H, Rijken M, Bekkers MJ, Kerssens JJ, Dekker J, van Berge Henegouwen GP. Social position of adolescents with chronic digestive disorders. Eur J Gastroenterol Hepatol 2002; 14: 543-549 [PMID: 11984153 DOI: 10.1097/00042737-20]
40. Marri SR, Buchman AL. The education and employment status of patients with inflammatory bowel diseases. Inflamm Bowel Dis 2005; 11: 171-177 [PMID: 15677911 DOI: 10.1097/0]
41. Longobardi T, Jacobs P, Bernstein CN. Work losses related to inflammatory bowel disease in the United States: results from the National Health Interview Survey. Am J Gastroenterol 2003; 98: 1064-1072 [PMID: 12809829]
42. Longobardi T, Jacobs P, Wu L, Bernstein CN. Work losses related to inflammatory bowel disease in Canada: results from a National Population Health Survey. Am J Gastroenterol 2003; 98: 844-849 [PMID: 12738466 DOI: 10.1111/ j.1572-0241.2003.07378.x]
43. Pirinen T, Kolho KL, Simola P, Ashorn M, Aronen ET. Parent and self-report of sleep-problems and daytime tiredness among adolescents with inflammatory bowel disease and their population-based controls. Sleep 2010; 33: 1487-1493 [PMID: 21102990]
44. Bagby RM, Taylor GJ, Parker JD. The Twenty-item Toronto Alexithymia Scale--II. Convergent, discriminant, and concurrent validity. J Psychosom Res 1994; 38: 33-40 [PMID: 8126688]
45. Bagby RM, Parker JD, Taylor GJ. The twenty-item Toronto Alexithymia Scale--I. Item selection and cross-validation of the factor structure. J Psychosom Res 1994; 38: 23-32 [PMID: 8126686]
46. Jones MP, Wessinger S, Crowell MD. Coping strategies and interpersonal support in patients with irritable bowel syndrome and inflammatory bowel disease. Clin Gastroenterol Hepatol 2006; 4: 474-481 [PMID: 16616353 DOI: 10.1016/ j.cgh.2005.12.012]
47. Moreno-Jiménez B, López Blanco B, Rodríguez-Muñoz A, Garrosa Hernández E. The influence of personality factors on health-related quality of life of patients with inflammatory bowel disease. J Psychosom Res 2007; 62: 39-46 [PMID: 17188119]
48. Flett GL, Baricza C, Gupta A, Hewitt PL, Endler NS. Perfectionism, psychosocial impact and coping with irritable bowel disease: a study of patients with Crohn's disease and ulcerative colitis. J Health Psychol 2011; 16: 561-571 [PMID: 21346015 DOI: 10.1177/1359105310383601]
49. Boye B, Lundin KE, Leganger S, Mokleby K, Jantschek G, Jantschek I, Kunzendorf S, Benninghoven D, Sharpe M, Wilhelmsen I, Blomhoff S, Malt UF, Jahnsen J. The INSPIRE study: do personality traits predict general quality of life (Short form-36) in distressed patients with ulcerative colitis and Crohn's disease? Scand J Gastroenterol 2008; 43: 1505-1513 [PMID: 18777439 DOI: 10.1080/00365520802321196]
50. Porcelli P, Taylor GJ, Bagby RM, De Carne M. Alexithymia and functional gastrointestinal disorders. A comparison with inflammatory bowel disease. Psychother Psychosom 1999; 68: 263-269 [PMID: 10516531 DOI: 10.1159/000012342]
51. Sajadinejad MS, Asgari K, Molavi H, Kalantari M, Adibi P. Psychological issues in inflammatory bowel disease: an overview. Gastroenterol Res Pract 2012; 2012: 106502 [PMID: 22778720 DOI: 10.1155/2012/106502]
52. Attree EA, Dancey CP, Keeling D, Wilson C. Cognitive function in people with chronic illness: inflammatory bowel disease and irritable bowel syndrome. Appl Neuropsychol 2003; 10: 96-104 [PMID: 12788684 DOI: 10.1207/S15324826AN]
53. Castaneda AE, Tuulio-Henriksson A, Aronen ET, Marttunen M, Kolho KL. Cognitive functioning and depressive symptoms in adolescents with inflammatory bowel disease. World J Gastroenterol 2013; 19: 1611-1617 [PMID: 23538788 DOI: 10.3748/wjg.v19.i10.1611]
54. Hansen RA, Gartlehner G, Lohr KN, Gaynes BN, Carey TS. Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder. Ann Intern Med 2005; 143: 415-426 [PMID: 16172440 DOI: 10.7326/0003-4819- 143-6-200509200-00006]
55. Mikocka-Walus AA, Turnbull DA, Moulding NT, Wilson IG, Andrews JM, Holtmann GJ. Antidepressants and inflammatory bowel disease: a systematic review. Clin Pract Epidemiol Ment Health 2006; 2: 24 [PMID: 16984660 DOI: 10.1186/1745-0179-2-24]
56. Mikocka-Walus AA, Turnbull DA, Moulding NT, Wilson IG, Andrews JM, Holtmann GJ. "It doesn't do any harm, but patients feel better": a qualitative exploratory study on gastroenterologists' perspectives on the role of antidepressants in inflammatory bowel disease. BMC Gastroenterol 2007; 7: 38 [PMID: 17892587 DOI: 10.1186/1471-230X-7-38]
57. Mikocka-Walus AA, Gordon AL, Stewart BJ, Andrews JM. The role of antidepressants in the management of inflammatory bowel disease (IBD): a short report on a clinical casenote audit. J Psychosom Res 2012; 72: 165-167 [PMID: 22281460 DOI: 10.1016/j.jpsychores.2011.06.006]
58. Mikocka-Walus AA, Gordon AL, Stewart BJ, Andrews JM. A magic pill? A qualitative analysis of patients' views on the role of antidepressant therapy in inflammatory bowel disease (IBD). BMC Gastroenterol 2012; 12: 93 [PMID: 22816728 DOI: 10.1186/1471-230X-12-93]
59. Mikocka-Walus AA, Turnbull DA, Moulding NT, Wilson IG, Holtmann GJ, Andrews JM. Does psychological status influence clinical outcomes in patients with inflammatory bowel disease (IBD) and other chronic gastroenterological diseases: an observational cohort prospective study. Biopsychosoc Med 2008; 2: 11 [PMID: 18538012]
60. Goodhand JR, Greig FI, Koodun Y, McDermott A, Wahed M, Langmead L, Rampton DS. Do antidepressants influence the disease course in inflammatory bowel disease? A retrospective case-matched observational study. Inflamm Bowel Dis 2012; 18: 1232-1239 [PMID: 22234954 DOI: 10.1002/ ibd.21846]
61. Bryant RV, van Langenberg DR, Holtmann GJ, Andrews JM. Functional gastrointestinal disorders in inflammatory bowel disease: impact on quality of life and psychological status. J Gastroenterol Hepatol 2011; 26: 916-923 [PMID: 21214889 DOI: 10.1111/j.1440-1746.2011.06624.x]
62. Mikocka-Walus AA, Turnbull DA, Andrews JM, Moulding NT, Holtmann GJ. The effect of functional gastrointestinal disorders on psychological comorbidity and quality of life in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2008; 28: 475-483 [PMID: 18532989 DOI: 10.1111/ j.1365-2036.2008.03754.x]
63. Ruepert L, Quartero AO, de Wit NJ, van der Heijden GJ, Rubin G, Muris JW. Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev 2011; (8): CD003460 [PMID: 21833945 DOI: 10.1002/14651858.CD003460.pub3]
64. Vismari L, Alves GJ, Palermo-Neto J. Amitriptyline and acute inflammation: a study using intravital microscopy and the carrageenan-induced paw edema model. Pharmacology 2010; 86: 231-239 [PMID: 20881447 DOI: 10.1159/000317064]
65. Guaiana G, Barbui C, Hotopf M. Amitriptyline for depression. Cochrane Database Syst Rev 2007; (3): CD004186 [PMID: 17636748 DOI: 10.1002/14651858.CD004186]
66. Tai YH, Tsai RY, Lin SL, Yeh CC, Wang JJ, Tao PL, Wong CS. Amitriptyline suppresses neuroinflammation-dependent interleukin-10-p38 mitogen-activated protein kinase-heme oxygenase-1 signaling pathway in chronic morphine-infused rats. Anesthesiology 2009; 110: 1379-1389 [PMID: 19417613 DOI: 10.1097/ALN.0b013e31819fccd5]
67. Rahimi HR, Shiri M, Razmi A. Antidepressants can treat inflammatory bowel disease through regulation of the nuclear factor-κB/nitric oxide pathway and inhibition of cytokine production: A hypothesis. World J Gastrointest Pharmacol Ther 2012; 3: 83-85 [PMID: 23494719 DOI: 10.4292/wjgpt.v3.i6.83]
68. Shelton RC. The nature of the discontinuation syndrome associated with antidepressant drugs. J Clin Psychiatry 2006; 67 Suppl 4: 3-7 [PMID: 16683856]
69. Haddad PM. Do antidepressants cause dependence? Epidemiol Psichiatr Soc 2005; 14: 58-62 [PMID: 16001701]
70. Bell RA, Franks P, Duberstein PR, Epstein RM, Feldman MD, Fernandez y Garcia E, Kravitz RL. Suffering in silence: reasons for not disclosing depression in primary care. Ann Fam Med 2011; 9: 439-446 [PMID: 21911763 DOI: 10.1370/ afm.1277]
71. Brown C, Battista DR, Bruehlman R, Sereika SS, Thase ME, Dunbar-Jacob J. Beliefs about antidepressant medications in primary care patients: relationship to self-reported adherence. Med Care 2005; 43: 1203-1207 [PMID: 16299431]
72. Russell J, Kazantzis N. Medication beliefs and adherence to antidepressants in primary care. N Z Med J 2008; 121: 14-20 [PMID: 19098944]
73. Gartlehner G, Thieda P, Hansen RA, Gaynes BN, Deveaugh- Geiss A, Krebs EE, Lohr KN. Comparative risk for harms of second-generation antidepressants: a systematic review and meta-analysis. Drug Saf 2008; 31: 851-865 [PMID: 18759509]
74. Hirschfeld RM. Long-term side effects of SSRIs: sexual dysfunction and weight gain. J Clin Psychiatry 2003; 64 Suppl 18: 20-24 [PMID: 14700451]
75. Bull SA, Hu XH, Hunkeler EM, Lee JY, Ming EE, Markson LE, Fireman B. Discontinuation of use and switching of antidepressants: influence of patient-physician communication. JAMA 2002; 288: 1403-1409 [PMID: 12234237 DOI: 10.1001/ jama.288.11.1403]
76. Zimmerman M, Posternak MA, Attiullah N, Friedman M, Boland RJ, Baymiller S, Berlowitz SL, Rahman S, Uy KK, Singer S, Chelminski I. Why isn't bupropion the most frequently prescribed antidepressant? J Clin Psychiatry 2005; 66: 603-610 [PMID: 15889947]
77. Graff LA, Walker JR. Psychological factors in inflammatory bowel disease. In: Bernstein C, editor. The Inflammatory Bowel Disease Yearbook. London: Remedica, 2007: 99-150
78. Kast RE, Altschuler EL. Remission of Crohn's disease on bupropion. Gastroenterology 2001; 121: 1260-1261 [PMID: 11706830]
79. Talmadge J, Scott R, Castelli P, Newman-Tarr T, Lee J. Molecular pharmacology of the beta-adrenergic receptor on THP-1 cells. Int J Immunopharmacol 1993; 15: 219-228 [PMID: 8096834 DOI: 10.1016/0192-0561(93)90098-J]
80. Lieb J. Remission of rheumatoid arthritis and other disorders of immunity in patients taking monoamine oxidase inhibitors. Int J Immunopharmacol 1983; 5: 353-357 [PMID: 6629596 DOI: 10.1016/0192-0561(83)90039-5]
81. Kast RE. Anti- and pro-inflammatory considerations in antidepressant use during medical illness: bupropion lowers and mirtazapine increases circulating tumor necrosis factoralpha levels. Gen Hosp Psychiatry 2003; 25: 495-496 [PMID: 14706417 DOI: 10.1016/S0163-8343(03)00093-8]
82. Kane S, Altschuler EL, Kast RE. Crohn's disease remission on bupropion. Gastroenterology 2003; 125: 1290 [PMID: 14552325 DOI: 10.1016/j.gastro.2003.02.004]
83. de Abajo FJ, Rodríguez LA, Montero D. Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study. BMJ 1999; 319: 1106-1109 [PMID: 10531103]
84. de Jong JC, van den Berg PB, Tobi H, de Jong-van den Berg LT. Combined use of SSRIs and NSAIDs increases the risk of gastrointestinal adverse effects. Br J Clin Pharmacol 2003; 55: 591-595 [PMID: 12814454 DOI: 10.1046/ j.0306-5251.2002.01770.x]
85. Dalton SO, Johansen C, Mellemkjaer L, Nørgård B, Sørensen HT, Olsen JH. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population- based cohort study. Arch Intern Med 2003; 163: 59-64 [PMID: 12523917 DOI: 10.1001/archpsyc.65.7.795]
86. de Abajo FJ, García-Rodríguez LA. Risk of upper gastrointestinal tract bleeding associated with selective serotonin reuptake inhibitors and venlafaxine therapy: interaction with nonsteroidal anti-inflammatory drugs and effect of acid-suppressing agents. Arch Gen Psychiatry 2008; 65: 795-803 [PMID: 18606952 DOI: 10.1001/archinte.163.1.59]
87. Lewis JD, Strom BL, Localio AR, Metz DC, Farrar JT, Weinrieb RM, Nessel L, Brensinger C, Kimmel SE. Moderate and high affinity serotonin reuptake inhibitors increase the risk of upper gastrointestinal toxicity. Pharmacoepidemiol Drug Saf 2008; 17: 328-335 [PMID: 18188866 DOI: 10.1002/pds.1546]
88. Opatrny L, Delaney JA, Suissa S. Gastro-intestinal haemorrhage risks of selective serotonin receptor antagonist therapy: a new look. Br J Clin Pharmacol 2008; 66: 76-81 [PMID: 18460039 DOI: 10.1111/j.1365-2125.2008.03154.x]
89. O'connor JF, Daniels G, Karush A, Moses L, Flood C, Stern LO. The effects of psychotherapy on the course of ulcerative colitis--a preliminary report. Am J Psychiatry 1964; 120: 738-742 [PMID: 14115464]
90. Jantschek G, Zeitz M, Pritsch M, Wirsching M, Klör HU, Studt HH, Rasenack J, Deter HC, Riecken EO, Feiereis H, Keller W. Effect of psychotherapy on the course of Crohn' s disease. Results of the German prospective multicenter psychotherapy treatment study on Crohn's disease. German Study Group on Psychosocial Intervention in Crohn' s Disease. Scand J Gastroenterol 1998; 33: 1289-1296 [PMID: 9930393]
91. Graff LA, Walker JR, Bernstein CN. Depression and anxiety in inflammatory bowel disease: a review of comorbidity and management. Inflamm Bowel Dis 2009; 15: 1105-1118 [PMID: 19161177 DOI: 10.1002/ibd.20873]
92. Timmer A, Preiss JC, Motschall E, Rücker G, Jantschek G, Moser G. Psychological interventions for treatment of inflammatory bowel disease. Cochrane Database Syst Rev 2011; (2): CD006913 [PMID: 21328288 DOI: 10.1002/14651858. CD006913.pub2]
93. Schmidt CF. Hypnotic suggestions and imaginations in the treatment of colitis ulcerosa. Hypnos 1992; 19: 237-242
94. Schwarz SP, Blanchard EB. Evaluation of a psychological treatment for inflammatory bowel disease. Behav Res Ther 1991; 29: 167-177 [PMID: 2021379]
95. Maunder RG, Esplen MJ. Supportive-expressive group psychotherapy for persons with inflammatory bowel disease. Can J Psychiatry 2001; 46: 622-626 [PMID: 11582823]
96. Pallis AG, Vlachonikolis IG, Mouzas IA. Assessing healthrelated quality of life in patients with inflammatory bowel disease, in Crete, Greece. BMC Gastroenterol 2002; 2: 1 [PMID: 11866863 DOI: 10.1186/1471-230X-2-1]
97. Bennebroek Evertsz' F, Bockting CL, Stokkers PC, Hinnen C, Sanderman R, Sprangers MA. The effectiveness of cognitive behavioral therapy on the quality of life of patients with inflammatory bowel disease: multi-center design and study protocol (KL!C- study). BMC Psychiatry 2012; 12: 227 [PMID: 23237076 DOI: 10.1186/1471-244X-12-227]
98. Höie O, Wolters F, Riis L, Aamodt G, Solberg C, Bernklev T, Odes S, Mouzas IA, Beltrami M, Langholz E, Stockbrügger R, Vatn M, Moum B. Ulcerative colitis: patient characteristics may predict 10-yr disease recurrence in a European-wide population-based cohort. Am J Gastroenterol 2007; 102: 1692-1701 [PMID: 17555460 DOI: 10.1111/ j.1572-0241.2007.01265.x]
99. Larsson K, Lööf L, Rönnblom A, Nordin K. Quality of life for patients with exacerbation in inflammatory bowel disease and how they cope with disease activity. J Psychosom Res 2008; 64: 139-148 [PMID: 18222127 DOI: 10.1016/j.jpsych ores.2007.10.007]
100. Jäghult S, Saboonchi F, Johansson UB, Wredling R, Kapraali M. Identifying predictors of low health-related quality of life among patients with inflammatory bowel disease: comparison between Crohn's disease and ulcerative colitis with disease duration. J Clin Nurs 2011; 20: 1578-1587 [PMID: 21418363 DOI: 10.1111/j.1365-2702.2010.03614.x]
101. Bennebroek Evertsz' F, Thijssens NA, Stokkers PC, Grootenhuis MA, Bockting CL, Nieuwkerk PT, Sprangers MA. Do Inflammatory Bowel Disease patients with anxiety and depressive symptoms receive the care they need? J Crohns Colitis 2012; 6: 68-76 [PMID: 22261530 DOI: 10.1016/ j.crohns.2011.07.006]
102. Beck AT. The current state of cognitive therapy: a 40-year retrospective. Arch Gen Psychiatry 2005; 62: 953-959 [PMID: 16143727 DOI: 10.1001/archpsyc.62.9.953]
103. Osborn RL, Demoncada AC, Feuerstein M. Psychosocial interventions for depression, anxiety, and quality of life in cancer survivors: meta-analyses. Int J Psychiatry Med 2006; 36: 13-34 [PMID: 16927576]
104. Snoek FJ, Skinner TC. Psychological counselling in problematic diabetes: does it help? Diabet Med 2002; 19: 265-273 [PMID: 11942996 DOI: 10.1046/j.1464-5491.2002.00678.x]
105. Szigethy E, Carpenter J, Baum E, Kenney E, Baptista-Neto L, Beardslee WR, Demaso DR. Case study: longitudinal treatment of adolescents with depression and inflammatory bowel disease. J Am Acad Child Adolesc Psychiatry 2006; 45: 396-400 [PMID: 16601643 DOI: 10.1097/01.chi.0000198591.45949.a4]
106. Szigethy E, Whitton SW, Levy-Warren A, DeMaso DR, Weisz J, Beardslee WR. Cognitive-behavioral therapy for depression in adolescents with inflammatory bowel disease: a pilot study. J Am Acad Child Adolesc Psychiatry 2004; 43: 1469-1477 [PMID: 15564816]
107. Szigethy E, Kenney E, Carpenter J, Hardy DM, Fairclough D, Bousvaros A, Keljo D, Weisz J, Beardslee WR, Noll R, De- Maso DR. Cognitive-behavioral therapy for adolescents with inflammatory bowel disease and subsyndromal depression. J Am Acad Child Adolesc Psychiatry 2007; 46: 1290-1298 [PMID: 17885570 DOI: 10.1097/chi.0b013e3180f6341f]
108. Díaz Sibaja MA, Comeche Moreno MI, Mas Hesse B. [Protocolized cognitive-behavioural group therapy for inflammatory bowel disease]. Rev Esp Enferm Dig 2007; 99: 593-598 [PMID: 18052663]
109. Maunder RG, Levenstein S. The role of stress in the development and clinical course of inflammatory bowel disease: epidemiological evidence. Curr Mol Med 2008; 8: 247-252 [PMID: 18537632 DOI: 10.2174/156652408784533832]
110. Maunder RG. Evidence that stress contributes to inflammatory bowel disease: evaluation, synthesis, and future directions. Inflamm Bowel Dis 2005; 11: 600-608 [PMID: 15905709 DOI: 10.1097/01.MIB.0000161919.42878.a0]
111. von Wietersheim J, Kessler H. Psychotherapy with chronic inflammatory bowel disease patients: a review. Inflamm Bowel Dis 2006; 12: 1175-1184 [PMID: 17119392]
112. Langhorst J, Mueller T, Luedtke R, Franken U, Paul A, Michalsen A, Schedlowski M, Dobos GJ, Elsenbruch S. Effects of a comprehensive lifestyle modification program on quality- of-life in patients with ulcerative colitis: a twelve-month follow-up. Scand J Gastroenterol 2007; 42: 734-745 [PMID: 17505996 DOI: 10.1080/00365520601101682]
113. Oxelmark L, Magnusson A, Löfberg R, Hillerås P. Groupbased intervention program in inflammatory bowel disease patients: effects on quality of life. Inflamm Bowel Dis 2007; 13: 182-190 [PMID: 17206698]
114. Deter HC, Keller W, von Wietersheim J, Jantschek G, Duchmann R, Zeitz M. Psychological treatment may reduce the need for healthcare in patients with Crohn's disease. Inflamm Bowel Dis 2007; 13: 745-752 [PMID: 17230495 DOI: 10.1002/ ibd.20068]
115. Kunzendorf S, Jantschek G, Straubinger K, Heberlein I, Homann N, Ludwig D, Benninghoven D. The Luebeck interview for psychosocial screening in patients with inflammatory bowel disease. Inflamm Bowel Dis 2007; 13: 33-41 [PMID: 17206637 DOI: 10.1002/ibd.20050]
116. Miehsler W, Weichselberger M, Offerlbauer-Ernst A, Dejaco C, Reinisch W, Vogelsang H, Machold K, Stamm T, Gangl A, Moser G. Which patients with IBD need psychological interventions? A controlled study. Inflamm Bowel Dis 2008; 14: 1273-1280 [PMID: 18393373]
117. Travis SP, Stange EF, Lémann M, Oresland T, Chowers Y, Forbes A, D'Haens G, Kitis G, Cortot A, Prantera C, Marteau P, Colombel JF, Gionchetti P, Bouhnik Y, Tiret E, Kroesen J, Starlinger M, Mortensen NJ. European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut 2006; 55 Suppl 1: i16-i35 [PMID: 16481629 DOI: 10.1136/gut.2005.081950b]
118. Greenberg GR, Feagan BG, Martin F, Sutherland LR, Thomson AB, Williams CN, Nilsson LG, Persson T. Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group. N Engl J Med 1994; 331: 836-841 [PMID: 8078529 DOI: 10.1056/NEJM199409293311303]
119. Otley A, Steinhart AH. Budesonide for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2005; (4): CD000296 [PMID: 16235274 DOI: 10.1002/14651858. CD000296.pub2]
120. Thomsen OO, Cortot A, Jewell D, Wright JP, Winter T, Veloso FT, Vatn M, Persson T, Pettersson E. A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group. N Engl J Med 1998; 339: 370-374 [PMID: 9691103]
121. Campieri M, Ferguson A, Doe W, Persson T, Nilsson LG. Oral budesonide is as effective as oral prednisolone in active Crohn's disease. The Global Budesonide Study Group. Gut 1997; 41: 209-214 [PMID: 9301500]
122. Rutgeerts P, Löfberg R, Malchow H, Lamers C, Olaison G, Jewell D, Danielsson A, Goebell H, Thomsen OO, Lorenz- Meyer H. A comparison of budesonide with prednisolone for active Crohn's disease. N Engl J Med 1994; 331: 842-845 [PMID: 8078530 DOI: 10.1056/NEJM199409293311304]
123. Bar-Meir S, Chowers Y, Lavy A, Abramovitch D, Sternberg A, Leichtmann G, Reshef R, Odes S, Moshkovitz M, Bruck R, Eliakim R, Maoz E, Mittmann U. Budesonide versus prednisone in the treatment of active Crohn's disease. The Israeli Budesonide Study Group. Gastroenterology 1998; 115: 835-840 [PMID: 9753485]
124. Modigliani R, Mary JY, Simon JF, Cortot A, Soule JC, Gendre JP, Rene E. Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Thérapeutique des Affections Inflammatoires Digestives. Gastroenterology 1990; 98: 811-818 [PMID: 2179031]
125. Gross V, Andus T, Caesar I, Bischoff SC, Lochs H, Tromm A, Schulz HJ, Bär U, Weber A, Gierend M, Ewe K, Schölmerich J. Oral pH-modified release budesonide versus 6-methylprednisolone in active Crohn's disease. German/Austrian Budesonide Study Group. Eur J Gastroenterol Hepatol 1996; 8: 905-909 [PMID: 8889459]
126. Pearson DC, May GR, Fick G, Sutherland LR. Azathioprine for maintaining remission of Crohn's disease. Cochrane Database Syst Rev 2000; (2): CD000067 [PMID: 10796482 DOI: 10.1002/14651858.CD000067]
127. Steinhart AH, Feagan BG, Wong CJ, Vandervoort M, Mikolainis S, Croitoru K, Seidman E, Leddin DJ, Bitton A, Drouin E, Cohen A, Greenberg GR. Combined budesonide andantibiotic therapy for active Crohn's disease: a randomized controlled trial. Gastroenterology 2002; 123: 33-40 [PMID: 12105831 DOI: 10.1053/gast.2002.34225]
128. Fraser AG. Methotrexate: first-line or second-line immunomodulator? Eur J Gastroenterol Hepatol 2003; 15: 225-231 [PMID: 12610315]
129. Rutgeerts P, D'Haens G, Targan S, Vasiliauskas E, Hanauer SB, Present DH, Mayer L, Van Hogezand RA, Braakman T, DeWoody KL, Schaible TF, Van Deventer SJ. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999; 117: 761-769 [PMID: 10500056]
130. Rutgeerts P, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Hanauer SB. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004; 126: 402-413 [PMID: 14762776 DOI: 10.1053/ j.gastro.2003.11.014]